undamentalytics Newsletter
Sign in

Scienture Holdings, Inc. income statement

In fiscal 2025, Scienture Holdings, Inc. reported revenue of $431,609, up 215.9% on the year before, operating income of −$42.6m (a -9867.9% margin) and net income of −$41.5m, or −$1.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11323471710101001
Cost of revenue—————0311551000
Gross profit01323356560001
Research and development———————————222
General and administrative22333347221785
Operating income−2−1−0−10−00−3−5−3−4−15−43−40
Interest expense00000000001143
Income before tax——————————−8−19−44—
Income tax———————————−1−2—
Net income−2−2−1−300−0−3−5−3−189−42−38
Diluted EPS−$0.21−$0.01−$0.11−$0.02$0.00$0.00−$0.02−$0.01−$0.02−$0.19−$2.92$0.31−$1.35−$1.29
Diluted shares (average)10m11m11m11m12m12m13m16m17m18m19m29m31m30m
EBITDA−2−1−0−10—0−3−5−3−4−15−42−39

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SCNX vs SXTPSCNX vs SXTCLPCN vs SCNXAKAN vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Scienture Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Scienture Holdings, Inc.